This trial is active, not recruiting.

Condition depression
Treatments fluoxetine (prozac), cognitive therapy (ct), placebo
Sponsor National Institute of Mental Health (NIMH)
Start date December 2003
End date December 2010
Trial size 500 participants
Trial identifier NCT00218764, DSIR 83-ATSO, R01 MH69618


This study will evaluate the longer term effectiveness of cognitive therapy (CT) versus medication treatment or placebo for prevention of recurrence of depression for 24 months after termination of continuation phase therapy.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification efficacy study
Intervention model parallel assignment
Masking double blind (subject, outcomes assessor)
Primary purpose treatment
Participants will receive treatment with cognitive therapy during the continuation phase
cognitive therapy (ct) CT or CBT
Participants will attend CT sessions every-other week for 8 weeks, then monthly for 6 months.
Participants will receive treatment with active fluoxetine during the continuation phase
fluoxetine (prozac) Prozac
Fluoxetine 10 to 40 mg/day for 8 months
(Placebo Comparator)
Patients participants will receive placebo in the continuation phase
Placebo daily for 8 months

Primary Outcomes

Depressive relapse
time frame: Measured at Month 24

Secondary Outcomes

Psychosocial functioning
time frame: Measured at Month 24

Eligibility Criteria

Male or female participants from 18 years up to 70 years old.

Inclusion Criteria: - Diagnosis of recurrent unipolar major depressive disorder - At least 2 episodes of major depression within lifetime, including present episode - Speaks and reads English - Seeking cognitive therapy treatment - At least one period of complete inter-episode recovery or a history of dysthymia prior to the onset of the presenting or past episodes Exclusion Criteria: - Active alcohol or other substance dependence within the 6 months prior to study entry - Active suicidal ideation with possible intent or probable risk - Mood disorder due to a medical condition or substance use, bipolar disorder, schizophrenia, or schizoaffective disorder - Unable to stop mood altering medications - Concurrent medication or exclusionary medical disorders (diabetes, head injury, stroke, cancer, multiple sclerosis) that may cause depression - Unable to attend clinic during business hours (Monday-Thursday, 8am-5pm) twice weekly - Unable to complete questionnaires - Unsuccessful treatment after 8 weeks of cognitive therapy with a certified therapist - Unsuccessful treatment after 6 weeks of 40 mg of fluoxetine (Prozac) - Pregnant or plans to become pregnant in the next 11-12 months

Additional Information

Official title Are CT's Effects Durable?
Principal investigator Michael E. Thase, MD
Description Depression is a serious medical illness that is often difficult to diagnose and treat. It often recurs more than once in a person's lifetime. Effective treatment methods are needed to prevent the relapse in people who have had prior episodes of depression. CT is a short-term talking therapy that focuses on changing negative thinking patterns and helping patients develop coping skills to deal with their experiences. Evidence suggests that CT is effective in treating a number of psychiatric conditions, including anxiety and anger. This study will determine the effectiveness of booster sessions of CT versus antidepressant medication in preventing relapse of depression in people at risk for recurrent depression. All participants in this double blind study will first receive 16 to 20 sessions of cognitive-behavioral therapy over 12 weeks. Participants who respond to the treatment, but do not achieve full remission of depressive symptoms, will be considered to be at risk for relapse. They will be randomly assigned to receive 10 booster sessions of one of three treatments over 8 months: cognitive-behavioral therapy, fluoxetine, or placebo. The booster sessions will take place twice monthly for the first 2 months and once monthly for the next 6 months. All participants who complete the entire 8 months of the study will be followed-up for an additional 2 years to monitor depressive relapse and psychosocial functioning.
Trial information was received from ClinicalTrials.gov and was last updated in October 2008.
Information provided to ClinicalTrials.gov by National Institute of Mental Health (NIMH).